Abbott Laboratories
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more
Loading news...
Loading more...
Sign in to download news snippet
The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.
Read full articleNo data available for this time period.
Change the time range to see results.
The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.
Read full article
ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.
Read full article
On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a
Read full article
AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,789 shares of the healthcare product maker's stock after acquiring an additional 11,649 shares during the period. AlTi
Read full article
ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.
Read full article
On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a
Read full article
AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,789 shares of the healthcare product maker's stock after acquiring an additional 11,649 shares during the period. AlTi
Read full article
Allworth Financial LP raised its holdings in Abbott Laboratories (NYSE: ABT) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,783 shares of the healthcare product maker's stock after purchasing an additional 14,018 shares during the quarter. Allworth Financial
Read full article
ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.
Read full article
CenterBook Partners LP bought a new position in shares of Abbott Laboratories (NYSE: ABT) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 6,403 shares of the healthcare product maker's stock, valued at approximately $633,000. A number of other large investors also
Read full article
ABT's UltiSynq lead combines conduction system pacing and defibrillation, with strong clinical trial results supporting its potential to expand the company's cardiac rhythm management portfolio.
Read full article
Allen Investment Management LLC cut its stake in shares of Abbott Laboratories (NYSE: ABT) by 45.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,000 shares of the healthcare product maker's stock after selling 6,700 shares during the quarter. Allen
Read full article
Ashton Thomas Private Wealth LLC boosted its stake in shares of Abbott Laboratories (NYSE: ABT) by 8.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,024 shares of the healthcare product maker's stock after acquiring an additional 5,216 shares during the
Read full article
Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year.
Read full article
No data available for this time period.
Change the time range to see results.